179 related articles for article (PubMed ID: 34298949)
1. Ipragliflozin Ameliorates Diabetic Nephropathy Associated with Perirenal Adipose Expansion in Mice.
Okuma H; Mori K; Nakamura S; Sekine T; Ogawa Y; Tsuchiya K
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298949
[TBL] [Abstract][Full Text] [Related]
2. Ipragliflozin-induced adipose expansion inhibits cuff-induced vascular remodeling in mice.
Mori K; Tsuchiya K; Nakamura S; Miyachi Y; Shiba K; Ogawa Y; Kitamura K
Cardiovasc Diabetol; 2019 Jun; 18(1):83. PubMed ID: 31234839
[TBL] [Abstract][Full Text] [Related]
3. Effects of the SGLT2 inhibitor ipragliflozin on various diabetic symptoms and progression of overt nephropathy in type 2 diabetic mice.
Tahara A; Takasu T
Naunyn Schmiedebergs Arch Pharmacol; 2018 Apr; 391(4):395-406. PubMed ID: 29374293
[TBL] [Abstract][Full Text] [Related]
4. A reduced M1-like/M2-like ratio of macrophages in healthy adipose tissue expansion during SGLT2 inhibition.
Miyachi Y; Tsuchiya K; Shiba K; Mori K; Komiya C; Ogasawara N; Ogawa Y
Sci Rep; 2018 Oct; 8(1):16113. PubMed ID: 30382157
[TBL] [Abstract][Full Text] [Related]
5. Prevention of progression of diabetic nephropathy by the SGLT2 inhibitor ipragliflozin in uninephrectomized type 2 diabetic mice.
Tahara A; Takasu T
Eur J Pharmacol; 2018 Jul; 830():68-75. PubMed ID: 29702076
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION).
Nomiyama T; Shimono D; Horikawa T; Fujimura Y; Ohsako T; Terawaki Y; Fukuda T; Motonaga R; Tanabe M; Yanase T;
Endocr J; 2018 Aug; 65(8):859-867. PubMed ID: 29806620
[TBL] [Abstract][Full Text] [Related]
7. Unmasking a sustained negative effect of SGLT2 inhibition on body fluid volume in the rat.
Masuda T; Watanabe Y; Fukuda K; Watanabe M; Onishi A; Ohara K; Imai T; Koepsell H; Muto S; Vallon V; Nagata D
Am J Physiol Renal Physiol; 2018 Sep; 315(3):F653-F664. PubMed ID: 29790389
[TBL] [Abstract][Full Text] [Related]
8. Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/ SIRT1 Pathway.
Lee JY; Lee M; Lee JY; Bae J; Shin E; Lee YH; Lee BW; Kang ES; Cha BS
Diabetes Metab J; 2021 Nov; 45(6):921-932. PubMed ID: 33611885
[TBL] [Abstract][Full Text] [Related]
9. Ipragliflozin improves mitochondrial abnormalities in renal tubules induced by a high-fat diet.
Takagi S; Li J; Takagaki Y; Kitada M; Nitta K; Takasu T; Kanasaki K; Koya D
J Diabetes Investig; 2018 Sep; 9(5):1025-1032. PubMed ID: 29352520
[TBL] [Abstract][Full Text] [Related]
10. Marein ameliorates diabetic nephropathy by inhibiting renal sodium glucose transporter 2 and activating the AMPK signaling pathway in db/db mice and high glucose-treated HK-2 cells.
Guo Y; Ran Z; Zhang Y; Song Z; Wang L; Yao L; Zhang M; Xin J; Mao X
Biomed Pharmacother; 2020 Nov; 131():110684. PubMed ID: 33152903
[TBL] [Abstract][Full Text] [Related]
11. Acute and Direct Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glomerular Filtration Rate in Spontaneously Diabetic Torii Fatty Rats.
Takakura S; Takasu T
Biol Pharm Bull; 2019; 42(10):1707-1712. PubMed ID: 31582658
[TBL] [Abstract][Full Text] [Related]
12. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.
Komiya C; Tsuchiya K; Shiba K; Miyachi Y; Furuke S; Shimazu N; Yamaguchi S; Kanno K; Ogawa Y
PLoS One; 2016; 11(3):e0151511. PubMed ID: 26977813
[TBL] [Abstract][Full Text] [Related]
13. Andrographolide ameliorates diabetic nephropathy by attenuating hyperglycemia-mediated renal oxidative stress and inflammation via Akt/NF-κB pathway.
Ji X; Li C; Ou Y; Li N; Yuan K; Yang G; Chen X; Yang Z; Liu B; Cheung WW; Wang L; Huang R; Lan T
Mol Cell Endocrinol; 2016 Dec; 437():268-279. PubMed ID: 27378149
[TBL] [Abstract][Full Text] [Related]
14. The Sodium Glucose Cotransporter 2 Inhibitor Ipragliflozin Promotes Preferential Loss of Fat Mass in Non-obese Diabetic Goto-Kakizaki Rats.
Takasu T; Hayashizaki Y; Hirosumi J; Minoura H; Amino N; Kurosaki E; Takakura S
Biol Pharm Bull; 2017; 40(5):675-680. PubMed ID: 28458353
[TBL] [Abstract][Full Text] [Related]
15. Nephropathy in diabetic db/db mice is accelerated by high protein diet and improved by the SGLT2 inhibitor dapagliflozin.
Nørgaard SA; Briand F; Sand FW; Galsgaard ED; Søndergaard H; Sørensen DB; Sulpice T
Eur J Pharmacol; 2019 Oct; 860():172537. PubMed ID: 31310751
[TBL] [Abstract][Full Text] [Related]
16. SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in
Korbut AI; Taskaeva IS; Bgatova NP; Muraleva NA; Orlov NB; Dashkin MV; Khotskina AS; Zavyalov EL; Konenkov VI; Klein T; Klimontov VV
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32340263
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive renoprotective effects of ipragliflozin on early diabetic nephropathy in mice.
Kamezaki M; Kusaba T; Komaki K; Fushimura Y; Watanabe N; Ikeda K; Kitani T; Yamashita N; Uehara M; Kirita Y; Shiotsu Y; Sakai R; Fukuda T; Yamazaki M; Fukui M; Matoba S; Tamagaki K
Sci Rep; 2018 Mar; 8(1):4029. PubMed ID: 29507299
[TBL] [Abstract][Full Text] [Related]
18. Cyanidin-3-O-glucoside ameliorates diabetic nephropathy through regulation of glutathione pool.
Qin Y; Zhai Q; Li Y; Cao M; Xu Y; Zhao K; Wang T
Biomed Pharmacother; 2018 Jul; 103():1223-1230. PubMed ID: 29864902
[TBL] [Abstract][Full Text] [Related]
19. Sodium-glucose cotransporter 2 inhibition normalizes glucose metabolism and suppresses oxidative stress in the kidneys of diabetic mice.
Tanaka S; Sugiura Y; Saito H; Sugahara M; Higashijima Y; Yamaguchi J; Inagi R; Suematsu M; Nangaku M; Tanaka T
Kidney Int; 2018 Nov; 94(5):912-925. PubMed ID: 30021702
[TBL] [Abstract][Full Text] [Related]
20. Telmisartan Ameliorates Nephropathy in Metabolic Syndrome by Reducing Leptin Release From Perirenal Adipose Tissue.
Li H; Li M; Liu P; Wang Y; Zhang H; Li H; Yang S; Song Y; Yin Y; Gao L; Cheng S; Cai J; Tian G
Hypertension; 2016 Aug; 68(2):478-90. PubMed ID: 27296996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
